(Z)-endoxifen — Regulatory decision
H2 2026
Additionally, given the relatively small size of this impacted population, we expect to seek Orphan Drug designation for MAS in the second half of 2026.Source filing
ATOS biotech catalysts & pipeline
ATOSSA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
(Z)-endoxifen — IND submission
2H26
IND clearance anticipated in 2H26, Ph 2 initiation in 2027Source filing
(Z)-endoxifen — Topline data
4Q26
Enrollment completed, top line data anticipated in 4Q26Source filing
(Z)-endoxifen — Full data
1H27
Final Ph2 data anticipated in 1H27Source filing
(Z)-endoxifen — Topline data
Q3 2026
The follow up 24-month mammographic record review of participants was concluded as of March 31, 2026, and top-line durability data is expected to be received before the end of the third quarter of 2026.Source filing